IRWD — Ironwood Pharmaceuticals Share News
0.000.00%
Last trade - 00:00- $589.91m
- $895.78m
- $296.15m
Ironwood Pharmaceuticals Inc expected to post earnings of 27cents a share - Earnings Preview
Brief: Ironwood Pharmaceuticals Announces FDA Filing Acceptance Of New Drug Application For Linzess
Brief: Ironwood Pharmaceuticals Sees FY2023 Revenue $420 Mln-$435 Mln
U.S. RESEARCH ROUNDUP- Adobe, Costar, Verisign
Ironwood Pharmaceuticals Inc reports results for the quarter ended in September - Earnings Summary
Brief: Ironwood Pharmaceuticals Reports Strong Q3 Results Maintains Full Year 2022 Financial Guidance
Ironwood Pharmaceuticals Inc expected to post earnings of 26cents a share - Earnings Preview
Brief: Ironwood Pharmaceuticals Reports Positive Topline Data From Phase Iii Trial Of Linzess® (Linaclotide) In Pediatric Patients Aged 6-17 With Functional Constipation
Brief: Ironwood Pharmaceuticals Reports Second Quarter 2022 Results
Brief: S&P Dow Jones Indices Says Under Armour And IPG Photonics Will Replace Trinity Industries Inc. And Yelp Inc. Respectively In The S&P Midcap 400
Ironwood Pharmaceuticals Inc reports results for the quarter ended in March - Earnings Summary
Brief: Ironwood Pharmaceuticals Reports First Quarter 2022 Results
U.S. RESEARCH ROUNDUP-American Airlines, Fulton Financial, Hillman Solutions
U.S. RESEARCH ROUNDUP-Cognex, LKQ, Redfin
Ironwood Pharmaceuticals Inc reports results for the quarter ended in December - Earnings Summary
Brief: Ironwood Pharmaceuticals Reports Fourth Quarter And Full Year 2021 Results
Ironwood Pharmaceuticals Inc expected to post earnings of 35 cents a share - Earnings Preview
Brief: Ironwood Pharmaceuticals Provides Update On FY 2021 Financial Guidance And Announces FY 2022 Financial Guidance
Brief: Ironwood Pharmaceuticals Appoints Sravan Emany As CFO